Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 52 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: EXP Clear all
Enrolling by invitation Not applicable Interventional

To Drill or Not to Drill: Do Memory Drills Help Train the Ability to "Remember to Remember" in Veterans

NCT06656637
View directory record Official record
Conditions
Memory Deficit
Interventions
Memory Drilling, Compensatory Strategies, Cognitive Processing Therapy
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

NCT02883049
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Central Nervous System Leukemia, Testicular Leukemia
Interventions
Clofarabine, Cyclophosphamide, Cytarabine, Dasatinib, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Etoposide, Hydrocortisone Sodium Succinate, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Prednisone, Radiation Therapy, Thioguanine, Vincristine Sulfate
Drug · Other · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 31 Years
Enrollment
5,949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
209
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 22, 2026, 6:55 AM EDT
Suspended Phase 2 Interventional

Phase 2, Single-arm Trial of BMS-986340 in Association With Nivolumab, Trifluridine/Tipiracil and Bevacizumab for Patients Refractory to Standard of Care Treatment and With Microsatellite-stable Colorectal Cancer

NCT07011550
View directory record Official record
Conditions
Microsatellite-stable Colorectal Cancer, Standard of Care, Nivolumab, Bevacizumab
Interventions
Nivolumab, Bevacizumab, BMS-986340, Trifluridine + Tipiracil
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Not applicable Interventional

Levari Exp.20: 2D - Partial Feedback

NCT06355999
View directory record Official record
Conditions
Form Perception, Color Perception, Decision Making
Interventions
Color Feedback, Shape Feedback
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 13, 2024 · Synced Oct 22, 2026, 6:55 AM EDT
Not listed Not applicable Interventional

Using Real-Time Functional Brain Imaging to Enhance Recovery From TBI

NCT01908647
View directory record Official record
Conditions
Traumatic Brain Injury, Post Traumatic Stress Disorder
Interventions
RT fMRI, Cognitive Training, Control RT fMRI, Control Cognitive Training
Behavioral
Lead sponsor
Van Boven, Robert W., M.D.
Other
Eligibility
18 Years to 45 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Fort Hood, Texas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2014 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vestibular Rehabilitation and Otolith Dysfunction

NCT02652442
View directory record Official record
Conditions
Dizziness
Interventions
Centrifugation Distance, Centrifugation Duration, Centrifugation Schedule
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 69 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Mountain Home, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 6:55 AM EDT
Active, not recruiting Not applicable Interventional

Walking Exercise Sustainability Through Telehealth for Veterans With Lower-limb Amputation

NCT05412550
View directory record Official record
Conditions
Lower-Limb Amputation
Interventions
Exercise self-management, Attention control
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 89 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Not applicable Interventional Results available

Urgent Care Management of Respiratory Illness Enabled With Novel Testing Pathway

NCT05467007
View directory record Official record
Conditions
Viral Infection, Acute Respiratory Infection, Upper Resp Tract Infection
Interventions
BioFire® Respiratory Panel 2.1-EZ
Diagnostic Test
Lead sponsor
Andrew Meltzer
Other
Eligibility
7 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 22, 2026, 6:55 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer

NCT04115306
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
PMD-026, fulvestrant
Drug
Lead sponsor
Phoenix Molecular Designs
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
10
States / cities
Gilbert, Arizona • Duarte, California • Irvine, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Impact of MABT5102A on Brain Amyloid Load and Related Biomarkers in Patients With Mild to Moderate Alzheimer's Disease

NCT01397578
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MABT5102A, placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
22
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2017 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Not applicable Interventional

One-session Treatment for Spider Fears

NCT03410264
View directory record Official record
Conditions
Spider Phobia
Interventions
CR-EXP, EXP-CR, Stress Management
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 8, 2021 · Synced Oct 22, 2026, 6:55 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neural Basis of Sensory Learning: Brain Regions

NCT05079516
View directory record Official record
Conditions
Basic Science
Interventions
Theta burst transcranial magnetic stimulation
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 45 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 22, 2026, 6:55 AM EDT
Terminated Phase 4 Interventional Results available

The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination

NCT03367429
View directory record Official record
Conditions
Stroke, Muscle Spasticity
Interventions
Botox
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
30 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 29, 2021 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Not applicable Interventional

Methods for Managing Intrusive Thoughts

NCT03416504
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Gradual Exposure (EXP-G), Variable Exposure (EXP-V)
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 22, 2026, 6:55 AM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Scaffolding of Brain Operations

NCT05412901
View directory record Official record
Conditions
Behavioral Performance
Interventions
discrimination task
Other
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 50 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC

NCT03989115
View directory record Official record
Conditions
Solid Tumor
Interventions
RMC-4630, Cobimetinib, Drug: Osimertinib
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Not applicable Interventional

Mechanisms of Treatment Change in Panic Disorder and Agoraphobia

NCT03547180
View directory record Official record
Conditions
Panic Disorder With Agoraphobia
Interventions
Cognitive Therapy, Capnometry-Assisted Respiratory Training, In-vivo exposure
Behavioral
Lead sponsor
Southern Methodist University
Other
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2020 · Synced Oct 22, 2026, 6:55 AM EDT
Terminated Phase 1 Interventional

A Study to Evaluate the Safety and Effectiveness of ILIxadencel Administered Into Tumors in Combination With Checkpoint Inhibitor (CPI) in Patients With ADvanced Cancer

NCT03735290
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Non-small Cell Lung Cancer
Interventions
ilixadencel, Pembrolizumab
Biological · Drug
Lead sponsor
Mendus
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Coral Gables, Florida • Iowa City, Iowa • Louisville, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation

NCT02719574
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Interventions
FT-2102 (olutasidenib), Azacitidine, Cytarabine
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
19
States / cities
Los Angeles, California • Sacramento, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 22, 2026, 6:55 AM EDT
Not listed Not applicable Interventional

Anti-phobic and Safety Behaviors in the Treatment of Acrophobia

NCT02085343
View directory record Official record
Conditions
Specific Phobia
Interventions
EXP, EXP + SBF, EXP + SBF + AA
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 22, 2026, 6:55 AM EDT
Active, not recruiting Not applicable Interventional

Optimization of a mHealth Physical Activity Promotion Intervention With Mindful Awareness for AYAO (OPT2MOVE)

NCT05375162
View directory record Official record
Conditions
Cancer
Interventions
Core Intervention, E-Coach, General Mindfulness Training, MVPA-Specific Mindfulness Training, Buddy
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 39 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Chicago, Illinois • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Project 3 Example: Human-AI Collaboration Tester (HAICT) Exp. 7

NCT05272189
View directory record Official record
Conditions
Decision Making, Computer Aided Diagnosis
Interventions
Simulated Second Reader AI, Target Prevalence
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 22, 2026, 6:55 AM EDT
Completed Phase 1 Interventional

BKM120 + Carboplatin + Paclitaxel for Patients With Advanced Solid Tumors

NCT01297452
View directory record Official record
Conditions
Solid Tumors
Interventions
BKM120 days 1 - 21 plus paclitaxel + carboplatin, BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin, BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1), BKM120, Paclitaxel + Carboplatin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2017 · Synced Oct 22, 2026, 6:55 AM EDT
Recruiting Phase 1 Interventional

Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

NCT07564232
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
Cyclophosphamide, Fludarabine, LNK001
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 22, 2026, 6:55 AM EDT